FDA Clearance Tracker · P170002
RHA 2, RHA 3, RHA 4
Last checked: Nov 20, 2026Latest source record: Oct 19, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Oct 19, 2017
Approved
Time to decision
275 days
Received Jan 17, 2017. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P170002
- Device name
- RHA 2, RHA 3, RHA 4
- Applicant
- Teoxane S.A.
- Applicant location
- Geneva
- Received
- Jan 17, 2017
- Decided
- Oct 19, 2017
- Decision
- Approved
- Supplements
- 55 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Implant, dermal, for aesthetic use (LMH)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for the RH-2. The RHA 2 is indicated for injection into the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLF), in adults aged 22 years or older. RHA 3 is indicated for injection into the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLF), in adults aged 22 years or older. RHA 4 is indicated for injection into the deep dermis to superficial subcutaneous tissue for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLF), in adults aged 22 years or older.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code LMH. The earliest in FDA's data is P800022, decided Jul 22, 1981.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Teoxane S.A.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- RHA Redensity® Eye Lido; RHA Redensity® EyePMA supplement
P170002-S050 · Decided May 12, 2026 · 256 days after receipt · Panel Track
Device type: Implant, dermal, for aesthetic use (LMH) · General & Plastic Surgery
- RHA® Dynamic Volume, RHA®4PMA supplement
P170002-S048 · Decided Sep 18, 2025 · 290 days after receipt · Panel Track
Device type: Implant, dermal, for aesthetic use (LMH) · General & Plastic Surgery
- RHA®3 dermal fillerPMA supplement
P170002-S030 · Decided Oct 27, 2023 · 179 days after receipt · Panel Track
Device type: Implant, dermal, for aesthetic use (LMH) · General & Plastic Surgery
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.